GNPX

Genprex, Inc. [GNPX] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

GNPX Stock Summary

Top 10 Correlated Stocks

GNPX

In the News

GNPX Financial details

Company Rating
-
Market Cap
5.12M
Income
-30.79M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
26
Optionable
No
Shortable
Yes
Earnings
22 May 2024
P/E
-0.43
Forward P/E
-
PEG
0.62
P/S
-
P/B
1.09
P/C
-
P/FCF
-0.57
Quick Ratio
2.7
Current Ratio
2.96
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-22.88
EPS next Y
-
EPS next Q
-
EPS this Y
-8.22%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-25.56%
-
-
-
-
SMA20
-
SMA50
-10%
SMA100
-40%
Inst Own
-
Inst Trans
-
ROA
-188%
ROE
-192%
ROC
-2.59%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
2.5-46.0
52W High
-86.38%
52W Low
+213.25%
RSI
44
Rel Volume
1.96
Avg Volume
88.29K
Volume
173.05K
Perf Week
-42.84%
Perf Month
-46.13%
Perf Quarter
-54.6%
Perf Half Y
-57.24%
-
-
-
-
Beta
-0.633
-
-
Volatility
1.29%, 6.58%
Prev Close
-5.65%
Price
6.265
Change
-9.47%

Something similar

Top by Market Cap
VTSAX
MSF.DE
GOOG
EMBASSY.NS
M&M.NS
Same Sector
SGTX
IMU.DE
AMPH
BOTHE.BR
KDNY
Top Correlated Stocks
TTOO
AVT.PA
TOM2.AS
Similar Market Cap
EEV
OIBRQ
ALSEI.PA
LMFA
ORG

Company Profile

Healthcare Biotechnology
  • Volume Average 88.29K
  • Market Capitalization 5.12M
  • Employee 26
  • CEO Mr. John Rodney Varner
  • Headquarters Austin,TX,US
  • IPO Date 2018-03-29
  • Website https://www.genprex.com

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.